oral
-
Investigational oral MS therapy significantly reduced relapse rate
Findings from two-year phase 3 trial published in New England Journal of Medicine.
oral | 06 October 2011
-
4SC, Yakult Honsha announce license agreement for oral inhibitor in Japan
4SC AG and Yakult Honsha Co Ltd announced the grant of an exclusive license by 4SC to Yakult Honsha for the development and commercialization of resminostat in Japan. Resminostat, an oral, pan-histone deacetylase (HDAC) inhibitor, is currently being …
oral | 15 April 2011
-
Long term oral therapy for endometriosis launched in Singapore
Women with endometriosis were given fresh hope with the launch of Visanne, said to be the world's first and only long term oral therapy proven to reduce endometriosis lesion and pain. Speaking at a media conference, Associate Professor Bernard Ch…
oral | 29 March 2011
-
Clinical study for investigational oral antiplatelet
AstraZeneca is initiating a large, international, clinical outcomes study for the investigational oral antiplatelet, ticagrelor (BRILINTA/BRILIQUE) in collaboration with the Brigham and Women’s Hospital-based Thrombolysis in Myocardial Infarction …
oral | 26 October 2010
-
ISPE Releases Oral Solid Dosage Forms Baseline Guide
ISPE has announced the release of its Oral Solid Dosage (OSD) Forms Baseline Guide, Second Edition. This second edition updates content from the original Guide to current industry standards, practices, and regulatory requirements. Specificall…
oral | 01 January 2010
-
Oral Drug Demonstrates Effectiveness in Animal Models of Human Pancreatic Cancer
Critical Outcome Technologies has announced positive results from animal experiments that were carried out at a Canadian cancer research facility. This series of experiments adds to the data package for COTI-2, demonstrating efficacy as a single agen…
oral | 18 December 2009
-
S*Bio: Jak2 Inhibitor Demonstrates Safety in Studies for Myeloproliferative Disorder
S*BIO has announced data presentations on its oral JAK2 inhibitor, SB1518. Data will be presented on the clinical results from the Phase 1 dose-escalation trial of SB1518 detailing its safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) …
oral | 09 December 2009
-
Advancell: Absorption and Oral Toxicity
Advancell develops, produces and commercializes cell-based in vitro models with predictive and regulatory value, to prove the efficacy, security and action mechanism of new molecules. Some of the in vitro models that are offered in the form …
oral | 01 October 2009
-
Angina Drug Reduces Incidences of Heart Attack
Findings in patients with angina who participated in the Beautiful study, show that there is a 42 percent reduction in heart attack with Procoralan (ivabradine). This benefit was particularly marked in patients with a resting heart rate >= 70 beats p…
oral | 18 September 2009
-
Encap Agrees to Colonic Drug Delivery Licensing Deal
Encap Drug Delivery has entered into a licensing agreement with The School of Pharmacy, University of London for the use of their drug delivery system, Phloral. This coating technology is designed to target the release of drugs to the colon and w…
oral | 11 September 2009
